Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Quest Diagnostics (DGX)

Quest Diagnostics prices $1.85 billion of senior notes to help fund LifeLabs acquisition

Neutral Impact 4 of 5 financing Written later

Quest Diagnostics issued $1.85 billion of senior notes in three tranches due 2027, 2029 and 2034, with the offering priced on August 15, 2024 and closing on August 19, 2024. The company said it intends to use the proceeds mainly to fund the purchase price of its previously announced LifeLabs acquisition, which adds debt tied to that deal.

Key points

  • $400 million of 4.600% senior notes due December 15, 2027, $600 million of 4.625% notes due 2029, and $850 million of 5.000% notes due 2034
  • If the LifeLabs acquisition is not completed by the Termination Date, the 2027 and 2029 notes must be redeemed at 101% of principal plus accrued interest; the 2034 notes remain outstanding
  • Interest is paid June 15 and December 15 each year, beginning December 15, 2024

The filing

CompanyQuest Diagnostics (DGX)
Form8-K, current report
Filed with the SECAug 19, 2024, 4:33 PM ET
Accession number0001104659-24-090867

Items reported: 1.01 Material Definitive Agreement5.03 Bylaw / Charter Amendment8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 19, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.